Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cel-Sci Corp (NY: CVM ) 1.080 -0.010 (-0.92%) Official Closing Price Updated: 8:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cel-Sci Corp < Previous 1 2 3 Next > CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer October 01, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation September 16, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress September 10, 2024 From CEL-SCI Corporation Via Business Wire The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance September 04, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results August 15, 2024 From CEL-SCI Corporation Via Business Wire BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering August 02, 2024 Via Investor Brand Network Exposures Product Safety CEL-SCI Announces Closing of $10.8 Million Offering July 29, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Announces Pricing of $10.8 Million Offering July 26, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results July 26, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Appoints Robert Watson as Chairperson of the Board July 08, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population June 18, 2024 From CEL-SCI Corporation Via Business Wire Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor June 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results May 16, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer May 08, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Appoints Mario Gobbo to Its Board of Directors April 23, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology March 19, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Issues Letter to Shareholders March 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results February 15, 2024 From CEL-SCI Corporation Via Business Wire InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering February 14, 2024 Via Investor Brand Network Exposures Product Safety CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock February 13, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock February 09, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug February 06, 2024 From CEL-SCI Corporation Via Business Wire European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® January 31, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments December 22, 2023 From CEL-SCI Corporation Via Business Wire UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer December 04, 2023 From CEL-SCI Corporation Via Business Wire CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock November 20, 2023 From CEL-SCI Corporation Via Business Wire CEL-SCI Announces Pricing of $5 Million Offering of Common Stock November 16, 2023 From CEL-SCI Corporation Via Business Wire CEL-SCI Issues Letter to Shareholders October 30, 2023 From CEL-SCI Corporation Via Business Wire Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments October 24, 2023 EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals October 24, 2023 From CEL-SCI Corporation Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.